• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Merck advances lung cancer attack, pocketing $170M from Daiichi and plotting ADC-trispecific combo

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 06, 2024 at 11:22: AM
via Merck & Co. has quickly recouped some of the costs of its Harpoon Therapeutics buyout, pulling in $170 million upfront by incorporating the lead candidate into a co-development deal with Daiichi Sankyo.

article source
 




Top Bottom
Back
Quote